Novel Medication Improves Lipid and Liver Health
In a Phase 2 trial, DR10624 — a first-of-its-kind agent that targets FGF21, glucagon, and GLP-1 pathways — significantly lowered …
Pipeline Progress in PBC Pruritus Treatments
At the EASL Congress 2025, hepatology experts highlighted new therapies aimed at pruritus (intense itching), a debilitating symptom of primary …